Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832634 · ClinicalTrials.gov registry record · NA
Fetal Genome Profiling Via Trophoblast Cells
A NA study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03832634 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 1 participants.
The verdict
NCT03832634, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objective of this study is to utilize trophoblast cells accumulating in the endocervical canal at the beginning of pregnancy for non-invasive prenatal testing. If we are able to validate that trophoblast cells obtained at an early gestational age can be reliably used for prenatal testing, there is great potential to improve early pregnancy management and counseling options for potential parents. The target population will be all women between the age of 18-45 undergoing care at the Center for Reproductive Medicine (CRM) in order to achieve a pregnancy.
Interventions
- DIAGNOSTIC_TEST Fetal Genome Profiling.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2023-02-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03832634
The ClinicalTrials.gov registry entry for NCT03832634 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fetal Genome Profiling. is the first listed.
NCT03832634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03832634 about?
NCT03832634 is a clinical study titled "Fetal Genome Profiling Via Trophoblast Cells". The objective of this study is to utilize trophoblast cells accumulating in the endocervical canal at the beginning of pregnancy for non-invasive prenatal testing. If we are able to validate that trophoblast cells obtained at an early gestational age can be reliably used for prenatal testing, there ...
What is the current status of trial NCT03832634?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-07-02. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT03832634?
The interventions under investigation include: Fetal Genome Profiling. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03832634?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.